Manufacturing cost refers to what it takes to actually build an insulin pump, including the parts and labor required. The table shows the expected low cost for basic models and the high cost for ...

Investing.com - Mizuho raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) to $22 from $21 while maintaining a Neutral rating on Thursday. The stock currently trades at $18.52, having surged ...

Portal Diabetes has received the US Food and Drug Administration (FDA) breakthrough device designation for its implantable insulin pump system, known as the Portal Pump. It has also initiated a Phase ...

CEO John Sheridan stated, "2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales while delivering on our mission to provide new innovations, improved outcomes ...

Feb 18 (Reuters) - Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.

HYDERABAD, India, Feb. 20, 2026 /PRNewswire/ -- According to the latest Mordor Intelligence report, the insulin delivery devices market size is estimated at USD 33.79 billion in 2026, and is expected ...